EMEA (Europe, Middle East and Africa) Antineoplastic Drugs Market Report 2017

October 2017 | 115 pages | ID: E61E848F160WEN
QYResearch

Abstracts

In this report, the EMEA Antineoplastic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Antineoplastic Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Antineoplastic Drugs market competition by top manufacturers/players, with Antineoplastic Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb
• Baxter Healthcare
• Boehringer Ingelheim
• Aspen Global
• Bayer AG
• Teva pharmaceutical Industries
• Johnson & Johnson
• Merc & Co.
• Pfize
• Accord Healthcare
• Genentech
• Lundbeck
• AbbVie

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• Chemotherapeutic Agents
• Biological/Immunotherapeutic Agents
• Personalized Medicine

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Antineoplastic Drugs for each application, including

• Hospitals
• Clinics
• Cancer Rehabilitation Centers
• Ambulatory Surgical Centers

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Antineoplastic Drugs Market Report 2017

1 ANTINEOPLASTIC DRUGS OVERVIEW

1.1 Product Overview and Scope of Antineoplastic Drugs
1.2 Classification of Antineoplastic Drugs
  1.2.1 EMEA Antineoplastic Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Antineoplastic Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Chemotherapeutic Agents
  1.2.4 Biological/Immunotherapeutic Agents
  1.2.5 Personalized Medicine
1.3 EMEA Antineoplastic Drugs Market by Application/End Users
  1.3.1 EMEA Antineoplastic Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospitals
  1.3.3 Clinics
  1.3.4 Cancer Rehabilitation Centers
  1.3.5 Ambulatory Surgical Centers
1.4 EMEA Antineoplastic Drugs Market by Region
  1.4.1 EMEA Antineoplastic Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Antineoplastic Drugs (2012-2022)
  1.5.1 EMEA Antineoplastic Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Antineoplastic Drugs Revenue and Growth Rate (2012-2022)

2 EMEA ANTINEOPLASTIC DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Antineoplastic Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Antineoplastic Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Antineoplastic Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Antineoplastic Drugs Sale Price by Players (2012-2017)
2.2 EMEA Antineoplastic Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Antineoplastic Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Antineoplastic Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Antineoplastic Drugs Sale Price by Type (2012-2017)
2.3 EMEA Antineoplastic Drugs (Volume) by Application
2.4 EMEA Antineoplastic Drugs (Volume and Value) by Region
  2.4.1 EMEA Antineoplastic Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Antineoplastic Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Antineoplastic Drugs Sales Price by Region (2012-2017)

3 EUROPE ANTINEOPLASTIC DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Antineoplastic Drugs Sales and Value (2012-2017)
  3.1.1 Europe Antineoplastic Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Antineoplastic Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Antineoplastic Drugs Sales and Market Share by Type
3.3 Europe Antineoplastic Drugs Sales and Market Share by Application
3.4 Europe Antineoplastic Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Antineoplastic Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Antineoplastic Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Antineoplastic Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST ANTINEOPLASTIC DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Antineoplastic Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Antineoplastic Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Antineoplastic Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Antineoplastic Drugs Sales and Market Share by Type
4.3 Middle East Antineoplastic Drugs Sales and Market Share by Application
4.4 Middle East Antineoplastic Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Antineoplastic Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Antineoplastic Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Antineoplastic Drugs Sales and Growth Rate (2012-2017)

5 AFRICA ANTINEOPLASTIC DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Antineoplastic Drugs Sales and Value (2012-2017)
  5.1.1 Africa Antineoplastic Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Antineoplastic Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Antineoplastic Drugs Sales and Market Share by Type
5.3 Africa Antineoplastic Drugs Sales and Market Share by Application
5.4 Africa Antineoplastic Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Antineoplastic Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Antineoplastic Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Antineoplastic Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Antineoplastic Drugs Sales and Growth Rate (2012-2017)

6 EMEA ANTINEOPLASTIC DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Hoffmann-La Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Antineoplastic Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Hoffmann-La Roche Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Amgen
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Antineoplastic Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Amgen Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Bristol-Myers Squibb
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Antineoplastic Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Bristol-Myers Squibb Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Baxter Healthcare
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Antineoplastic Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Baxter Healthcare Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Boehringer Ingelheim
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Antineoplastic Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Boehringer Ingelheim Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Aspen Global
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Antineoplastic Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Aspen Global Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Bayer AG
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Antineoplastic Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Bayer AG Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Teva pharmaceutical Industries
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Antineoplastic Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Teva pharmaceutical Industries Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Johnson & Johnson
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Antineoplastic Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Johnson & Johnson Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Merc & Co.
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Antineoplastic Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Merc & Co. Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Pfize
6.12 Accord Healthcare
6.13 Genentech
6.14 Lundbeck
6.15 AbbVie

7 ANTINEOPLASTIC DRUGS MANUFACTURING COST ANALYSIS

7.1 Antineoplastic Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Antineoplastic Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Antineoplastic Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Antineoplastic Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA ANTINEOPLASTIC DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Antineoplastic Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Antineoplastic Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Antineoplastic Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Antineoplastic Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Antineoplastic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Antineoplastic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Antineoplastic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Antineoplastic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Antineoplastic Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Antineoplastic Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Antineoplastic Drugs
Figure EMEA Antineoplastic Drugs Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Antineoplastic Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Chemotherapeutic Agents Product Picture
Figure Biological/Immunotherapeutic Agents Product Picture
Figure Personalized Medicine Product Picture
Figure EMEA Antineoplastic Drugs Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Antineoplastic Drugs by Application in 2016
Figure Hospitals Examples
Table Key Downstream Customer in Hospitals
Figure Clinics Examples
Table Key Downstream Customer in Clinics
Figure Cancer Rehabilitation Centers Examples
Table Key Downstream Customer in Cancer Rehabilitation Centers
Figure Ambulatory Surgical Centers Examples
Table Key Downstream Customer in Ambulatory Surgical Centers
Figure EMEA Antineoplastic Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Antineoplastic Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Antineoplastic Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Antineoplastic Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Antineoplastic Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Antineoplastic Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Antineoplastic Drugs Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Antineoplastic Drugs Sales Share by Players (2012-2017)
Figure 2016 Antineoplastic Drugs Sales Share by Players
Figure 2017 Antineoplastic Drugs Sales Share by Players
Figure EMEA Antineoplastic Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Antineoplastic Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Antineoplastic Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Antineoplastic Drugs Revenue Share by Players
Table 2017 EMEA Antineoplastic Drugs Revenue Share by Players
Table EMEA Antineoplastic Drugs Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Antineoplastic Drugs Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Antineoplastic Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Antineoplastic Drugs by Type (2012-2017)
Figure EMEA Antineoplastic Drugs Sales Market Share by Type (2012-2017)
Table EMEA Antineoplastic Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Antineoplastic Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Antineoplastic Drugs by Type in 2016
Table EMEA Antineoplastic Drugs Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Antineoplastic Drugs Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Antineoplastic Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Antineoplastic Drugs by Application (2012-2017)
Figure EMEA Antineoplastic Drugs Sales Market Share by Application in 2016
Table EMEA Antineoplastic Drugs Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Antineoplastic Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Antineoplastic Drugs by Region (2012-2017)
Figure EMEA Antineoplastic Drugs Sales Market Share in 2016
Table EMEA Antineoplastic Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Antineoplastic Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Antineoplastic Drugs by Region (2012-2017)
Figure EMEA Antineoplastic Drugs Revenue Market Share Regions in 2016
Table EMEA Antineoplastic Drugs Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Antineoplastic Drugs Revenue and Growth Rate (2012-2017)
Table Europe Antineoplastic Drugs Sales (K Units) by Type (2012-2017)
Table Europe Antineoplastic Drugs Market Share by Type (2012-2017)
Figure Europe Antineoplastic Drugs Market Share by Type in 2016
Table Europe Antineoplastic Drugs Sales (K Units) by Application (2012-2017)
Table Europe Antineoplastic Drugs Market Share by Application (2012-2017)
Figure Europe Antineoplastic Drugs Market Share by Application in 2016
Table Europe Antineoplastic Drugs Sales (K Units) by Countries (2012-2017)
Table Europe Antineoplastic Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Antineoplastic Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Antineoplastic Drugs Sales Market Share by Countries in 2016
Table Europe Antineoplastic Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Antineoplastic Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Antineoplastic Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Antineoplastic Drugs Revenue Market Share by Countries in 2016
Figure Germany Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure France Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UK Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Antineoplastic Drugs Sales (K Units) by Type (2012-2017)
Table Middle East Antineoplastic Drugs Market Share by Type (2012-2017)
Figure Middle East Antineoplastic Drugs Market Share by Type (2012-2017)
Table Middle East Antineoplastic Drugs Sales (K Units) by Applications (2012-2017)
Table Middle East Antineoplastic Drugs Market Share by Applications (2012-2017)
Figure Middle East Antineoplastic Drugs Sales Market Share by Application in 2016
Table Middle East Antineoplastic Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Antineoplastic Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Antineoplastic Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Antineoplastic Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Antineoplastic Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Antineoplastic Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Antineoplastic Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Antineoplastic Drugs Sales (K Units) by Type (2012-2017)
Table Africa Antineoplastic Drugs Sales Market Share by Type (2012-2017)
Figure Africa Antineoplastic Drugs Sales Market Share by Type (2012-2017)
Figure Africa Antineoplastic Drugs Sales Market Share by Type in 2016
Table Africa Antineoplastic Drugs Sales (K Units) by Application (2012-2017)
Table Africa Antineoplastic Drugs Sales Market Share by Application (2012-2017)
Figure Africa Antineoplastic Drugs Sales Market Share by Application (2012-2017)
Table Africa Antineoplastic Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Africa Antineoplastic Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Antineoplastic Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Antineoplastic Drugs Sales Market Share by Countries in 2016
Table Africa Antineoplastic Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Antineoplastic Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Antineoplastic Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Antineoplastic Drugs Revenue Market Share by Countries in 2016
Figure South Africa Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Table Hoffmann-La Roche Antineoplastic Drugs Basic Information List
Table Hoffmann-La Roche Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Hoffmann-La Roche Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Hoffmann-La Roche Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Hoffmann-La Roche Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Amgen Antineoplastic Drugs Basic Information List
Table Amgen Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Amgen Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Amgen Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Bristol-Myers Squibb Antineoplastic Drugs Basic Information List
Table Bristol-Myers Squibb Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Bristol-Myers Squibb Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Baxter Healthcare Antineoplastic Drugs Basic Information List
Table Baxter Healthcare Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Baxter Healthcare Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Baxter Healthcare Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Baxter Healthcare Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Boehringer Ingelheim Antineoplastic Drugs Basic Information List
Table Boehringer Ingelheim Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Boehringer Ingelheim Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Boehringer Ingelheim Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Boehringer Ingelheim Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Aspen Global Antineoplastic Drugs Basic Information List
Table Aspen Global Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Aspen Global Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Aspen Global Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Aspen Global Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Bayer AG Antineoplastic Drugs Basic Information List
Table Bayer AG Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bayer AG Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Bayer AG Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Bayer AG Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Teva pharmaceutical Industries Antineoplastic Drugs Basic Information List
Table Teva pharmaceutical Industries Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Teva pharmaceutical Industries Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Teva pharmaceutical Industries Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Teva pharmaceutical Industries Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Johnson & Johnson Antineoplastic Drugs Basic Information List
Table Johnson & Johnson Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Johnson & Johnson Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Johnson & Johnson Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Johnson & Johnson Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Merc & Co. Antineoplastic Drugs Basic Information List
Table Merc & Co. Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merc & Co. Antineoplastic Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Merc & Co. Antineoplastic Drugs Sales Market Share in EMEA (2012-2017)
Figure Merc & Co. Antineoplastic Drugs Revenue Market Share in EMEA (2012-2017)
Table Pfize Antineoplastic Drugs Basic Information List
Table Accord Healthcare Antineoplastic Drugs Basic Information List
Table Genentech Antineoplastic Drugs Basic Information List
Table Lundbeck Antineoplastic Drugs Basic Information List
Table AbbVie Antineoplastic Drugs Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Antineoplastic Drugs
Figure Manufacturing Process Analysis of Antineoplastic Drugs
Figure Antineoplastic Drugs Industrial Chain Analysis
Table Raw Materials Sources of Antineoplastic Drugs Major Manufacturers in 2016
Table Major Buyers of Antineoplastic Drugs
Table Distributors/Traders List
Figure EMEA Antineoplastic Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Antineoplastic Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Antineoplastic Drugs Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Antineoplastic Drugs Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Antineoplastic Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Antineoplastic Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Antineoplastic Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Antineoplastic Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Antineoplastic Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Antineoplastic Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Antineoplastic Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Antineoplastic Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Antineoplastic Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Antineoplastic Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Antineoplastic Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Antineoplastic Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Antineoplastic Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Antineoplastic Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Antineoplastic Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Antineoplastic Drugs Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Antineoplastic Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Antineoplastic Drugs Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Antineoplastic Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources